Prolongevity
Prolongevity
Investing in technologies that extend human healthspan
The World Is Aging Faster Than Ever
By 2050, over 2 billion adults will be age 60 or older—a demographic shift unprecedented in human history. Asia is at the center of this transformation, with Japan, Singapore, South Korea, and China facing the world’s most rapidly aging societies.
Digital health and biology are converging to address this challenge, creating what may be the largest investment opportunity ever created. The economic value of targeting aging is estimated at $38 trillion to the global economy.
Our Portfolio Companies: Breakthrough Technologies Extending Human Healthspan
An AI platform for real-time genomic interpretation, enabling earlier diagnosis and better treatment decisions for age-related diseases. Used by over 1,700 healthcare organizations across 50 countries. Acquired by QIAGEN for $80M.
Real-time brain activity platform unlocking biomarkers for cognitive decline and neurological disease. Already deployed in clinical trials for an Alzheimer’s vaccine.
Detects silent heart risk factors before symptoms appear, addressing one of the world’s leading causes of death. Deployed across 800+ active clinical sites with almost zero churn.
AI predicts clinical trial outcomes before they begin—accelerating the development of treatments for age-related diseases. 12 of the top 20 global pharma companies are clients.
Built for Asian Markets
Japan has the world’s oldest population, with 29% over age 65. Singapore, South Korea, and Taiwan are following the same trajectory. These markets don’t just need longevity technologies—they’re deploying them at scale.
Our permanent presence across Asia enables real-world validation before we invest and rapid adoption after. We don’t build for hypothetical futures—we solve problems Asian healthcare systems face today.